← Back to Screener
Creative Medical Technology Holdings, Inc. Common Stock (CELZ)
Price$2.26
Favorite Metrics
Price vs S&P 500 (26W)-34.57%
Price vs S&P 500 (4W)24.75%
Market Capitalization$9.13M
All Metrics
Book Value / Share (Quarterly)$2.03
P/TBV (Annual)0.71x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-59.45%
Cash Flow / Share (Quarterly)$-1.58
Price vs S&P 500 (YTD)21.88%
Gross Margin (TTM)63.50%
Net Profit Margin (TTM)-58762.83%
EPS (TTM)$-2.49
10-Day Avg Trading Volume0.12M
EPS Excl Extra (TTM)$-2.49
Revenue Growth (5Y)-48.14%
EPS (Annual)$-2.52
ROI (Annual)-79.78%
Gross Margin (Annual)63.50%
Net Profit Margin (5Y Avg)-39703.89%
Cash / Share (Quarterly)$1.95
Revenue Growth QoQ (YoY)0.00%
ROA (Last FY)-76.77%
Revenue Growth TTM (YoY)-45.45%
EBITD / Share (TTM)$-2.45
ROE (5Y Avg)-18.70%
Operating Margin (TTM)-60104.33%
Cash Flow / Share (Annual)$-1.58
P/B Ratio1.22x
P/B Ratio (Quarterly)0.67x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)320.43x
Net Interest Coverage (TTM)-0.03x
ROA (TTM)-82.36%
EPS Incl Extra (Annual)$-2.52
Current Ratio (Annual)25.97x
Quick Ratio (Quarterly)25.49x
3-Month Avg Trading Volume0.07M
52-Week Price Return24.75%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.92
P/S Ratio (Annual)1521.80x
Asset Turnover (Annual)0.00x
52-Week High$6.25
Operating Margin (5Y Avg)-46248.59%
EPS Excl Extra (Annual)$-2.52
26-Week Price Return-25.83%
Quick Ratio (Annual)25.49x
13-Week Price Return33.51%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)25.97x
Enterprise Value$1.923
Revenue / Share Growth (5Y)-75.20%
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.00x
Pretax Margin (Annual)-99916.83%
Cash / Share (Annual)$1.95
3-Month Return Std Dev62.70%
Gross Margin (5Y Avg)58.92%
Net Income / Employee (TTM)$-1
ROE (Last FY)-79.78%
Net Interest Coverage (Annual)-0.35x
EPS Basic Excl Extra (Annual)$-2.52
Receivables Turnover (TTM)34.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.49
Receivables Turnover (Annual)32.00x
ROI (TTM)-85.66%
P/S Ratio (TTM)1521.80x
Pretax Margin (5Y Avg)-39703.89%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.92
Price vs S&P 500 (52W)-10.35%
Year-to-Date Return26.02%
5-Day Price Return13.82%
EPS Normalized (Annual)$-2.52
ROA (5Y Avg)-18.17%
Net Profit Margin (Annual)-99916.83%
Month-to-Date Return19.90%
Cash Flow / Share (TTM)$-6.88
EBITD / Share (Annual)$-2.53
Operating Margin (Annual)-102380.17%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-18.70%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.49
P/TBV (Quarterly)0.71x
P/B Ratio (Annual)0.67x
Inventory Turnover (TTM)2.00x
Pretax Margin (TTM)-58762.83%
Book Value / Share (Annual)$2.03
Price vs S&P 500 (13W)30.65%
Beta1.95x
Revenue / Share (TTM)$0.00
ROE (TTM)-85.66%
52-Week Low$1.50
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CELZCreative Medical Technology Holdings, Inc. Common Stock | 1521.80x | -45.45% | 63.50% | — | $2.26 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Creative Medical Technology Holdings Inc is a biotechnology company developing therapeutic applications of amniotic fluid-derived stem cells for regenerative medicine. The company targets reproductive and sexual health disorders, including male and female sexual dysfunction, infertility, and miscarriage-related conditions. Its business model centers on creating and licensing intellectual property in this specialized stem cell therapy space.